$60,000 per year in passive income from ASX dividend shares sits comfortably above ASFA’s modest retirement standard and within reach of the comfortable retirement benchmark for a single person.

The maths is straightforward.

To generate $60,000 per year in dividend income at an average yield of 5%, you need approximately $1.2 million invested.

At a 6% yield, you need $1 million.

Three ASX dividend shares offer different but complementary ways to build toward that target.

Telstra: the defensive anchor

Telstra Group Ltd (ASX: TLS) is the natural starting point for any ASX passive income portfolio.

Not because it offers the highest yield, but because it offers reliability.

Telstra has not cut its dividend since 2019 and has increased its annual payout every year since 2022.

CommSec consensus estimates point to a fully franked dividend of 21 cents per share in FY26, rising to 21.5 cents in FY27.

At $4.92 per share, that implies a forward yield of approximately 4.3%, or a grossed-up yield of approximately 6.1% including franking credits.

That franked income is particularly powerful inside superannuation, where franking credits arrive as cash rather than being absorbed by tax.

A $400,000 investment in Telstra at a 5.86% grossed-up yield generates approximately $23,440 per year.

Suncorp: the recovery play with a growing payout

Suncorp Group Ltd (ASX: SUN) had a difficult FY26.

Catastrophe costs ran to approximately $580 million above budget and weighing on near-term dividends.

Despite this, UBS forecasts a fully franked annual dividend of 66 cents per share for FY2026.

This would imply a grossed-up yield of approximately 5.0% at the current share price of $18.94.

The more compelling part for this ASX dividend share is the trajectory.

UBS projects Suncorp’s dividend climbing toward $1.09 per share by FY2030, implying a forward grossed-up yield of approximately 8.2% at today’s price.

That reflects a scenario where FY26’s elevated catastrophe costs are unlikely to repeat at the same scale, and where improving margins support a multi-year dividend recovery.

A $350,000 investment in Suncorp at a 5.0% grossed-up yield generates approximately $17,500 per year today. This should grow materially as the dividend recovers.

Amcor: the quarterly payer

Amcor Plc (ASX: AMC) brings something Telstra and Suncorp do not: quarterly dividends.

Most ASX companies pay twice yearly. Amcor pays four times per year, giving income investors a more frequent and consistent cash flow.

Amcor’s most recently declared quarterly dividend was 91 cents per share in AUD terms. This translates to an annualised payout of approximately A$3.64 per share.

At $63.92 per share, that implies a trailing yield of approximately 5.7%.

Unfortunately, that yield is unfranked, reflecting Amcor’s UK domicile and predominantly offshore earnings.

However, the yield more than compensates for the lack of franking at an absolute level.

The business is delivering too. In Q3 FY26, Amcor delivered net sales of US$5.91 billion, up 77% year-on-year, as Berry Global synergies continued to flow through.

A $320,000 investment in Amcor at 5.7% generates approximately $18,240 per year.

The portfolio maths for these ASX dividend shares

$400,000 in Telstra at 6.1% generates approximately $24,400 per year.

$350,000 in Suncorp at 5.0% generates approximately $17,500 per year.

$320,000 in Amcor at 5.7% generates approximately $18,240 per year.

Combined, a $1,070,000 portfolio across these three stocks generates approximately $60,140 per year, essentially hitting the $60,000 target.

Foolish takeaway

$60,000 in annual passive income from ASX dividend shares is achievable with approximately $1 million to $1.2 million invested across reliable, income-producing businesses.

Telstra provides the defensive anchor with franked income.

Suncorp provides the income growth trajectory.

Amcor provides the quarterly cash flow and global defensive exposure.

Income investors looking for high yield at a reasonable price don’t need to look much further than these three.

The post How to build $60,000 in annual passive income from ASX dividend shares appeared first on The Motley Fool Australia.

More reading

• These ASX shares could generate $10,000 per year in passive income
• Are Telstra shares a buy for passive income?
• How much do I need in my superannuation to get $6,000 per month in passive income?
• How much is needed in superannuation to target a $70,000 annual passive income?
• 5 of the best investments on the ASX right now to complement your superannuation

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Amcor Plc and Telstra Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) is one of Australia’s greatest corporate success stories.

For decades, the biotech company has built a global business around specialised medical products that solve serious healthcare problems. It has expanded internationally, developed valuable expertise, and become one of the country’s most recognised companies.

But great companies can still go through difficult periods.

Confidence lost

CSL has lost some of the market confidence it once enjoyed, with investors questioning growth expectations, execution, and whether the company can return to its previous level of performance.

The question for investors is whether this is a permanent change or an opportunity created by short-term disappointment.

I think CSL shares are worth buying in July.

A biotech business built on real needs

The reason I continue to like CSL is that its products are connected to genuine medical demand.

The company operates across plasma-derived therapies, vaccines, and specialist healthcare products. These are areas where patients and healthcare systems rely on effective treatments rather than temporary consumer trends.

That creates a different type of growth opportunity.

Healthcare demand tends to be supported by long-term forces such as ageing populations, improving access to treatment, and advances in medical technology.

CSL’s plasma business remains particularly important. Collecting plasma, manufacturing therapies, and supplying patients around the world requires significant infrastructure, expertise, and regulatory capability.

Those advantages have taken decades to build.

I think that is easy to overlook when investors are focused on short-term earnings pressure.

The market has become more cautious

CSL’s recent challenges are real. Investors have raised concerns around the performance of parts of the business, including Vifor, while also assessing the longer-term outlook for vaccines and plasma therapies.

Those concerns deserve attention. However, I think the market may have moved too far in the other direction.

CSL does not need to return to being viewed as a perfect growth company for its shares to perform well. It just needs to stabilise the business, improve execution, and show that its core strengths remain valuable.

That feels achievable to me.

One thing I like about CSL is that it operates in complex markets where experience is important. Competitors cannot simply appear overnight and replicate decades of research, manufacturing capability, regulatory knowledge, and global relationships.

Why this could be an opportunity

When a company with a strong history falls out of favour, investors often have to decide whether the problems are temporary or structural.

With CSL, I think it is a temporary issue and the long-term opportunity remains intact.

The company still operates in markets with significant unmet demand. It still has global scale. And it still has the expertise required to compete in highly specialised healthcare areas.

The recovery may take time. Investors may need patience while management continues improving the business and rebuilding confidence. The share price may not immediately reflect any progress, but I would argue the worst is now behind it.

Foolish takeaway

I think CSL is a fallen ASX giant worth buying in July.

The company has faced genuine challenges, and investors should not ignore them. But I think the strength of CSL’s underlying business, its global position, and the long-term demand for its products make it one of the more interesting recovery opportunities on the ASX.

Sometimes the best investments come from companies that have temporarily lost favour while their long-term advantages remain.

The post Is CSL a fallen ASX giant to buy in July? appeared first on The Motley Fool Australia.

More reading

• The only 3 ASX blue-chip shares I’d buy and hold until 2036
• July is historically one of the best months for ASX shares. Can July FY27 deliver?
• How to tell if an ASX share is cheap or a value trap
• 2 ASX healthcare shares crashing, now bouncing: buy, hold or sell?
• ASX healthcare shares have jumped 21% since June. Can the recovery continue?

Motley Fool contributor Grace Alvino has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Middle East conflict has entered a new phase.

Washington launched strikes against Iran in response to attacks on three commercial vessels in the Strait of Hormuz. This has reversed what had briefly appeared to be a path toward a negotiated peace just weeks earlier.

ASX shares initially slid lower, with broad selling pressure across materials, technology, and financial shares.

The energy sector is the notable exception.

On news of the new outbreak of conflict, WTI crude rose 2.66% to US$72.32 and Brent crude rose 2.55% to US$76.05 as supply disruption fears return.

Here is what that means for these energy focused ASX shares.

Woodside Energy Group Ltd (ASX: WDS)

Woodside shares were up yesterday, a strong move against a broadly falling market.

The company is the most direct ASX beneficiary of higher oil prices, with LNG and oil production revenue rising almost in lockstep with the global oil price.

The Scarborough LNG project is 94% complete with first cargo targeted for Q4 2026, adding earnings support at exactly the moment oil prices are recovering.

A sustained return to US$90 per barrel would upgrade Woodside’s second-half FY26 revenue and dividend capacity.

The risk is equally clear: another ceasefire could reverse the trade just as rapidly as it did in June for ASX shares.

Santos Ltd (ASX: STO)

Santos shares also surged yesterday, reflecting Santos’ historically higher sensitivity to oil price swings.

When the original peace deal broke in June, Santos fell 8% in a single session. Today’s move reflects the reverse trade as war risk returns.

The underlying business is not dependent on geopolitical volatility to perform.

The company’s Barossa LNG plant is already producing at 75% of planned 2026 production rates. Moreover, the first oil from Pikka Phase 1 in Alaska provides an additional production stream that should insulate cash flow regardless of where oil settles.

Northern Star Resources Ltd (ASX: NST)

Northern Star Resources may benefit from yesterday’s escalation in a different way.

Gold is the market’s preferred safe-haven asset in periods of geopolitical stress.

The gold price has already risen to US$4,187 per ounce in recent sessions, and renewed Middle East conflict adds a further layer of safe-haven demand.

Northern Star is Australia’s largest listed gold miner, and the Elliott Management activist campaign continues to add a corporate catalyst dimension, with calls for a strategic review still unresolved heading into FY27.

A gold price above US$4,000 combined with an in-depth strategic review gives Northern Star shareholders two potential catalysts for future growth.

The broader picture for ASX shares

Beyond energy and gold, the renewed escalation is weighing on the rest of the ASX.

BHP Group Ltd (ASX: BHP) was down yesterday as rising oil prices increase mining operating costs, while the four major banks were all under pressure yesterday morning.

The pattern is familiar: geopolitical escalation benefits energy and gold while weighing on almost everything else.

Foolish Takeaway for ASX shares

Washington’s fresh strikes on Iran have put supply risk back in the spotlight.

Woodside and Santos are today’s direct beneficiaries as oil prices climb.

Northern Star benefits through the safe-haven gold price tailwind.

How long any of these moves last depends entirely on whether diplomacy reasserts itself, as it has done multiple times already in 2026.

The post Washington just launched fresh strikes on Iran. Here is what that means for ASX shares appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Thursday
• Here are the top 10 ASX 200 shares today
• 5 things to watch on the ASX 200 on Wednesday
• 5 things to watch on the ASX 200 on Tuesday
• Oil price crash sparks broker upgrades for ASX energy shares

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.